A Review of Prostate Cancer and the Effect of Lutetium Radiopharmaceutical

 Prostate cancer is a type of disease in which malignant cells originate from prostate tissue and multiply irregularly and increasingly, leading to an increase in volume in each of the cellular components of the prostate gland.  

The search for studies published in Google Scholar, PubMed, ProQuest, Science Direct, and Elsevier sites was performed with the keywords prostate, radiopharmaceutical, cancer, and Lutetium. 

The synthesis of articles related to prostate cancer and lutetium drug showed that the average prevalence of this complication and follow-up of its treatment in Iranian articles with the Beck tool is 52.13%, and in foreign articles, equal to 78.21%.  

With the help of remarkable advances in bioinformatics & molecular methods, much information has been obtained that will help in the early recognition of cancer, and timely screening for some cancers helps in its early diagnosis. In general, today, scientists have concluded that they can get the best result by early diagnosis and complete removal of cancer cells before the spread of cancer. Prostate cancer is the most common type of cancer in men over the age of 50. Currently, researchers are unable to determine the exact cause of prostate cancer. DNA changes can be hereditary or caused by certain lifestyles that people have chosen. Lutetium-177 Prostate-specific membrane antigen  (PSMA), also called a prostate membrane-specific antigen, is becoming a popular treatment for men with advanced prostate cancer with metastatic (spread) or refractory tumors. This treatment method has successfully reduced the size of tumors (cancerous masses) in many patients. Lutetium-177 PSMA treatment (abbreviated as Lutetium) is a suitable treatment option for men undergoing radical prostatectomy or primary radiation therapy but still have disease recurrence and metastasis symptoms.